Management of imatinib-resistant patients with chronic myeloid leukemia

Pavan Kumar Bhamidipati, Hagop Kantarjian, Jorge Cortes, A. Megan Cornelison, Elias Jabbour

Research output: Contribution to journalReview article

Abstract

Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.

Original languageEnglish (US)
Pages (from-to)103-117
Number of pages15
JournalTherapeutic Advances in Hematology
Volume4
Issue number2
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
Research Personnel
Imatinib Mesylate

Keywords

  • CML
  • imatinib resistance
  • treatment
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Management of imatinib-resistant patients with chronic myeloid leukemia. / Bhamidipati, Pavan Kumar; Kantarjian, Hagop; Cortes, Jorge; Cornelison, A. Megan; Jabbour, Elias.

In: Therapeutic Advances in Hematology, Vol. 4, No. 2, 04.2013, p. 103-117.

Research output: Contribution to journalReview article

Bhamidipati, Pavan Kumar ; Kantarjian, Hagop ; Cortes, Jorge ; Cornelison, A. Megan ; Jabbour, Elias. / Management of imatinib-resistant patients with chronic myeloid leukemia. In: Therapeutic Advances in Hematology. 2013 ; Vol. 4, No. 2. pp. 103-117.
@article{f035cd8664ba44fab500ccfb72d63ebc,
title = "Management of imatinib-resistant patients with chronic myeloid leukemia",
abstract = "Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33{\%} of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.",
keywords = "CML, imatinib resistance, treatment, tyrosine kinase inhibitor",
author = "Bhamidipati, {Pavan Kumar} and Hagop Kantarjian and Jorge Cortes and Cornelison, {A. Megan} and Elias Jabbour",
year = "2013",
month = "4",
doi = "10.1177/2040620712468289",
language = "English (US)",
volume = "4",
pages = "103--117",
journal = "Therapeutic Advances in Hematology",
issn = "2040-6207",
number = "2",

}

TY - JOUR

T1 - Management of imatinib-resistant patients with chronic myeloid leukemia

AU - Bhamidipati, Pavan Kumar

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Cornelison, A. Megan

AU - Jabbour, Elias

PY - 2013/4

Y1 - 2013/4

N2 - Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.

AB - Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.

KW - CML

KW - imatinib resistance

KW - treatment

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84993699130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993699130&partnerID=8YFLogxK

U2 - 10.1177/2040620712468289

DO - 10.1177/2040620712468289

M3 - Review article

AN - SCOPUS:84993699130

VL - 4

SP - 103

EP - 117

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

SN - 2040-6207

IS - 2

ER -